Abstract
Reduced carbon monoxide diffusing capacity (DLCO) is common after recovery from severe COVID‐19 pneumonitis. The extent to which this relates to alveolar membrane dysfunction as opposed to vascular injury is uncertain. Simultaneous measurement of nitric oxide diffusing capacity (DLNO) and DLCO can partition gas diffusion into its two components: alveolar–capillary membrane conductance (DmCO) and capillary blood volume (VC). We sought to evaluate DmCO and VC in the early and later recovery periods after severe COVID‐19. Patients attended for post‐COVID‐19 clinical review and lung function testing including DLNO/DLCO. Repeat testing occurred when indicated and comparisons made using t‐tests. Forty‐nine (eight female) subjects (mean ± SD age: 58 ± 13, BMI: 34 ± 8) who had severe COVID‐19 pneumonitis, WHO severity classification of 6 ± 1, and prolonged (21 ± 22 days) hospital stay, were assessed 2 months (61 ± 35 days) post discharge. DLCOadj (z‐score −1.70 ± 1.49, 25/49 < lower limit of normal [LLN]) and total lung capacity (z‐score −1.71 ± 1.30) were both reduced. DmCO and VC and were reduced to a similar extent (z‐score −1.19 ± 1.05 and −1.41 ± 1.20, p = 0.4). Seventeen (one female) patients returned for repeat testing 4 months (122 ± 61 days) post discharge. In this subgroup with more impaired lung function, DLCOadj improved but remained below LLN (z‐score −3.15 ± 0.83 vs. −2.39 ± 0.86, p = 0.01), 5/17 improved to >LNN. DmCO improved (z‐score −2.05 ± 0.89 vs. −1.41 ± 0.78, p = 0.01) but VC was unchanged (z‐score −2.51 ± 0.55 vs. −2.29 ± 0.59, p = 0.16). Alveolar membrane conductance is abnormal in the earlier recovery phase following severe COVID‐19 but significantly improves. In contrast, reduced VC persists. These data raise the possibility that persisting effects of acute vascular injury may contribute to gas diffusion impairment long after severe COVID‐19 pneumonitis.
Keywords: capillary blood volume, COVID‐19, diffusing capacity, gas transfer
Simultaneous measurement of nitric oxide and carbon monoxide diffusing capacity (DLNO/DLCO) was used to quantify the contributions of alveolar–capillary membrane conductance and capillary blood volume (VC) to impaired gas diffusion following severe COVID‐19. At 2 months, both were reduced to a similar extent. Membrane conductance significantly improved at 4 months, however, VC remained reduced. These novel findings suggest persisting vascular injury may contribute to physiological impairment long after severe COVID‐19 pneumonitis.
1. INTRODUCTION
Infection with the delta variant of COVID‐19 was frequently associated with severe respiratory failure. For this and earlier variants, impaired gas exchange, reflected in reduced carbon monoxide diffusing capacity (DLCO), commonly persisted after the initial phase of recovery. Cohort studies have consistently found it to be the most prevalent lung function abnormality, reduced to a greater extent than either vital capacity or total lung capacity (TLC), and related to COVID‐19 disease severity (Thomas et al., 2021; Torres‐Castro et al., 2021). This persistent abnormality could be related to alveolar–capillary membrane dysfunction or vascular injury—the latter an intriguing possibility given the frequency of pulmonary embolism seen in acute COVID‐19 and contested arguments about the importance of microthromboembolism.
Effective gas diffusion from lung to circulation requires efficient transit across the alveolar membrane that is conjoined with an effectively perfused pulmonary capillary network. Of the two tracer gases most commonly used to measure gas diffusion, CO transfer is sensitive to changes in pulmonary capillary blood volume (VC), whereas NO transfer is more sensitive to the function of the alveolar membrane due in part to its significantly higher reaction rate with hemoglobin (θNO). Utilizing the Guenard equation (Guenard et al., 1987), the simultaneous measurement of DLNO and DLCO can quantify the primary components of gas diffusion: alveolar membrane conductance (DmCO) and VC (Zavorsky et al., 2017).
The simultaneous measurement of DLNO/DLCO is complex and not widely utilized. The available data are conflicting with some early studies reporting DLNO to be reduced to a greater extent than DLCO in a group with a broad range of severity post COVID‐19, suggesting a primary impairment in membrane conductance (Barisione & Brusasco, 2021; Nunez‐Fernandez et al., 2021). However, a recent study of a severe cohort reported a greater resistance in VC (Noel‐Savina et al., 2021). We sought to evaluate DmCO and VC in patients hospitalized for severe COVID‐19 pneumonitis in the early and later recovery periods.
2. METHODS
2.1. Patient characteristics and study design
This was a prospective, cohort, observational study. The study was approved by the Sydney Local Health District Human Ethics Review Board (LNR/14/CRGH/206, 2019/ETH07887, NSW, Australia) with waiver of consent.
All patients hospitalized with severe COVID‐19 pneumonitis at Concord Hospital were invited to attend an outpatient clinical review following discharge. Complex lung function was measured in all attending patients and electronic medical record data were accessed to document clinical and biochemical data pertaining to their COVID‐19 admission. Further outpatient clinical review and repeat testing occurred when indicated by their treating physician. Patients were excluded from analysis if they had known preexisting cardiopulmonary disease, recent respiratory tract infection other than COVID‐19, significant smoking history (>10 pack/year), claustrophobia, and inability to follow instruction or meet testing criteria.
2.2. Lung function
Spirometry, lung volumes via plethysmography, and DLCO adjusted for hemoglobin (DLCOadj) (Masterlab; Jaeger) (Hemocue) were performed according to the American Thoracic Society/European Respiratory Society recommendations (Graham et al., 2017, 2019; Wanger et al., 2005). Reference ranges were derived from the Global Lung Initiative (Hall et al., 2021; Quanjer et al., 2012; Stanojevic et al., 2017). Patients then performed simultaneous measurement of DLNO and DLCO (Hyp’ Air, Medisoft) during a 5 s breath‐hold according to ERS standards and compared to reference ranges from Zavorsky et al. (2017). The diffusion components, DmCO and VC, were calculated using Forster's equation (Guenard et al., 1987) with finite specific θNO = 4.5 mL min−1 mmHg−1 and 1/θCO as per Guenard et al. (2016), as recommended by ERS standards (Zavorsky et al., 2017). The lower limit of normal (LLN) of all lung function was considered the fifth percentile, that is, at −1.64 z‐score.
2.3. Statistical analysis
The normality of distribution of all variables was assessed by the Shapiro–Wilk test and then expressed as mean ± SD. Lung function when performed at two visits only was assessed using paired, two‐tailed t‐tests; when performed at three visits was assessed using repeated measures ANOVA, and between groups using unpaired, two‐tailed t‐tests. Clinical associations with lung function data were investigated using Spearman correlation analysis. A p < 0.05 was considered statistically significant.
3. RESULTS
3.1. Patient characteristics
Fifty‐seven (12 female) patients presented for outpatient clinical review following COVID‐19 hospitalization, with 49 (eight female) patients (mean ± SD) age 58 ± 13 years, height 169 ± 8, and BMI 34 ± 8 kg m−2 meeting testing criteria. The initial clinic assessment was 61 ± 35 days (~2 months) post discharge. Patients had severe COVID‐19 pneumonitis with WHO ordinal severity classification of 5.7 ± 1.1 (Rubio‐Rivas et al., 2022) and prolonged length of hospital stay (21 ± 22 days). Maximal required fraction of inspired oxygen was 48 ± 21% and 22 (45%) patients required noninvasive ventilation or intubation during admission. Peak C‐reactive protein, ferritin, and D‐dimer during the hospitalization were elevated (146 ± 93 mg/L, 1986 ± 3704 μg/L, and 5 ± 13 mg/L, respectively). As part of their COVID‐19 therapy, 41 (84%) patients received dexamethasone, 33 (67%) received baricitinib, nine (18%) received remdesivir and two (4%) received tocilizumab. A summary of patient characteristics is presented in Table 1.
TABLE 1.
Characteristics and lung function of 49 patients following severe COVID‐19 pneumonitis on initial respiratory review 2 months post discharge.
| All patients, 2 months post discharge, n = 49 | |||
|---|---|---|---|
| Number, female | 49, 12 | ||
| Age, years | 58.5 ± 12.7 | ||
| Height, cm | 169.4 ± 8.2 | ||
| BMI, kg m−2 | 34.0 ± 8.1 | ||
| Hemoglobin, g/L | 13.0 ± 1.47 | ||
| Days post discharge | 61 ± 35 | ||
| WHO ordinal severity, 0–8 | 5.7 ± 1.1 | ||
| Absolute | % reference | z‐score | |
| FEV1 L | 2.74 ± 0.72 | 87.2 ± 16.8 | −0.83 ± 1.19 |
| FVC L | 3.32 ± 0.92 | 83.1 ± 16.8 | −1.15 ± 1.21 |
| FEV1/FVC % | 83.2 ± 7.1 | — | 0.66 ± 1.08 |
| TLC L | 5.07 ± 0.97 | 79.3 ± 15.7 | −1.71 ± 1.30 |
| FRC L | 2.50 ± 0.49 | 78.2 ± 16.2 | −1.20 ± 0.96 |
| RV L | 1.75 ± 0.38 | 89.7 ± 20.6 | −0.46 ± 0.80 |
| DLCOadj mL min−1 mmHg−1 | 19.0 ± 5.9 | 76.1 ± 20.9 | −1.70 ± 1.49 |
| KCOadj mL min−1 mmHg−1 L−1 | 3.98 ± 0.69 | 90.6 ± 15.0 | — |
| DLNO mL min−1 mmHg−1 | 100.8 ± 33.5 | 72.0 ± 19.8 | −1.61 ± 1.25 |
| DmCO mL min−1 mmHg−1 | 97.7 ± 35.0 | 71.3 ± 21.5 | −1.19 ± 1.05 |
| VC mL | 47.3 ± 18.8 | 69.3 ± 24.2 | −1.41 ± 1.20 |
Abbreviations: BMI, body mass index; DLCOadj, carbon monoxide diffusing capacity adjusted for hemoglobin; DLNO, nitric oxide diffusion capacity; DmCO, CO alveolar membrane conductance; FEV1, forced expiratory volume in 1 s; FRC, function residual capacity; FVC, forced vital capacity; KCOadj, DLCOadj adjusted for alveolar volume; RV, residual volume; TLC, total lung capacity; VC, capillary blood volume; WHO, World Health Organization.
Seventeen (one female) patients (33%) returned for repeat testing (Visit 2) 122 ± 61 days (~4 months) since discharge. Seven male patients returned again for a third visit (Visit 3) 232 ± 61 days (~8 months) since discharge.
3.2. Lung function
Lung function in all patients on the initial respiratory review 2 months post discharge is presented in Table 1. Mean DLCOadj (76 ± 21% reference, −1.70 ± 1.49 z‐score) and TLC (79 ± 16% reference, −1.71 ± 1.30 z‐score) were both reduced. DmCO and VC were reduced to a similar extent (z‐score −1.19 ± 1.05 and −1.41 ± 1.20, p = 0.4). DLCOadj (r = −0.47, p = 0.01) and TLC (r = −0.47, p = 0.01) were negatively correlated with length of stay. VC was negatively correlated with length of stay (r = −0.42, p < 0.01). WHO severity negatively correlated with TLC only (r = −0.42, p = 0.01). Demographic and biochemical data during hospitalization did not correlate with lung function.
The patient subgroup that returned for repeat visits had worse lung function than those that did not return (Table 2), WHO ordinal disease severity (6.1 ± 0.7, p = 0.047) and longer length of stay (29.9 ± 16.3 days, p = 0.01) compared to those who attended a single visit. All patients in this subgroup presented with DLCOadj < LLN on initial review (56.7 ± 10.0% reference, −3.15 ± 0.83 z‐score) (Figure 1). In this subgroup, all primary measures of lung function improved between Visit 1 and Visit 2 (Table 2). DLCOadj improved but remained below LLN (−3.15 ± 0.83 [Visit 1] vs. −2.39 ± 0.86 [Visit 2] z‐score, p = 0.01). DmCO also improved (−2.05 ± 0.87 [Visit 1] vs. −1.41 ± 0.78 [Visit 2] z‐score, p = 0.01), however, VC was unchanged (−2.51 ± 0.55 [Visit 1] vs. −2.29 ± 0.59 [Visit 2] z‐score, p = 0.16) (Figure 2). DLNO/DLCO was at the higher range of normal (normal range: 3.8–5.8; Zavorsky et al., 2017) at Visit 1 (5.35 ± 0.25), and trended higher at Visit 2 but remained within normal range (5.42 ± 0.59) (p = 0.63).
TABLE 2.
Serial lung function in a subgroup of 17 patients following severe COVID‐19 pneumonitis.
| n = 17 (1 female) | 2 months post discharge | 4 months post discharge | p‐value (paired t‐test) |
|---|---|---|---|
| FEV1 | |||
| % reference | 78.0 ± 15.9 | 86.4 ± 19.4 | 0.01* |
| z‐score | −1.42 ± 1.29 | −0.83 ± 1.65 | 0.01* |
| FVC | |||
| % reference | 69.7 ± 13.0 | 79.9 ± 16.7 | 0.01* |
| z‐score | −2.08 ± 0.98 | −1.32 ± 1.36 | 0.01* |
| FEV1/FVC | |||
| % reference | 87.6 ± 2.8 | 84.5 ± 4.3 | 0.01* |
| z‐score | 1.42 ± 0.66 | 0.92 ± 0.94 | 0.01* |
| TLC | |||
| % reference | 66.2 ± 9.9 | 74.8 ± 11.9 | 0.01* |
| z‐score | −2.80 ± 0.81 | −2.07 ± 0.94 | 0.01* |
| FRC | |||
| % reference | 67.8 ± 14.6 | 71.7 ± 15.0 | 0.01* |
| z‐score | −1.82 ± 0.96 | −1.50 ± 0.81 | 0.01* |
| RV | |||
| % reference | 74.3 ± 10.5 | 82.0 ± 13.9 | 0.01* |
| z‐score | −1.02 ± 0.44 | −0.72 ± 0.50 | 0.01* |
| DLCOadj | |||
| % reference | 56.7 ± 10.0 | 65.7 ± 11.3 | 0.01* |
| z‐score | −3.15 ± 0.83 | −2.39 ± 0.86 | 0.01* |
| KCOadj | |||
| % reference | 84.1 ± 16.1 | 88.0 ± 15.6 | 0.02* |
| DLNO/DLCO | |||
| 5.35 ± 0.25 | 5.42 ± 0.59 | 0.63 | |
| DLNO | |||
| % reference | 52.1 ± 12.6 | 61.4 ± 11.8 | 0.01* |
| z‐score | −2.89 ± 0.72 | −2.38 ± 0.76 | 0.01* |
| DmCO | |||
| % reference | 52.8 ± 18.1 | 69.2 ± 16.6 | 0.01* |
| z‐score | −2.05 ± 0.87 | −1.41 ± 0.78 | 0.01* |
| VC | |||
| % reference | 48.9 ± 11.9 | 52.3 ± 14.5 | 0.27 |
| z‐score | −2.51 ± 0.55 | −2.29 ± 0.59 | 0.15 |
Abbreviations: DLCOadj, carbon monoxide diffusing capacity adjusted for hemoglobin; DLNO, nitric oxide diffusion capacity; DmCO, CO alveolar membrane conductance; FEV1, forced expiratory volume in 1 s; FRC, function residual capacity; FVC, forced vital capacity; KCOadj, DLCOadj adjusted for alveolar volume; RV, residual volume; TLC, total lung capacity; VC; capillary blood volume.
Met significance.
FIGURE 1.
Individual z‐score data points of carbon monoxide diffusion capacity adjusted for hemoglobin (DLCOadj) on initial respiratory review in 49 patients following severe COVID‐19 pneumonitis. Red color denotes subgroup with serial testing. LLN: lower limit of normal (broken line).
FIGURE 2.
Box and whisker (95% CI) z‐score of alveolar membrane conductance (DmCO), capillary blood volume (VC), carbon monoxide diffusion capacity adjusted for hemoglobin (DLCOadj), and total lung capacity (TLC), in 17 patients at 2 and 4 months recovery from severe COVID‐19 pneumonitis. LLN: lower limit of normal (broken line). p‐value: paired t‐test.
In the seven male patients that returned again for Visit 3, repeated measured identified an improvement in FVC, KCOadj, and DmCO from 2 to 8 months following discharge (Table 3).
TABLE 3.
Serial lung function in a subgroup of seven male patients following severe COVID‐19 pneumonitis.
| n = 7 male | 2 months post discharge | 4 months post discharge | 8 months post discharge | p‐value (repeated measures ANOVA) |
|---|---|---|---|---|
| Hemoglobin g/L | 12.5 ± 1.4 | 14.1 ± 1.4 | 14.4 ± 1.5 | 0.15 |
| FEV1 | ||||
| % reference | 86.0 ± 21.6 | 92.7 ± 28.7 | 97.7 ± 29.2 | 0.12 |
| FVC | ||||
| % reference | 77.0 ± 16.7 | 85.3 ± 24.1 | 91.1 ± 23.8 | 0.03* |
| FEV1/FVC | ||||
| % reference | 87.4 ± 2.9 | 84.6 ± 4.7 | 85.3 ± 5.8 | 0.20 |
| TLC a | ||||
| % reference | 70.6 ± 16.1 | 78.6 ± 18.1 | 83.6 ± 20.0 | 0.16 |
| FRC a | ||||
| % reference | 72.2 ± 23.0 | 77.8 ± 21.6 | 77.6 ± 25.0 | 0.22 |
| RV a | ||||
| % reference | 67.6 ± 11.5 | 75.0 ± 10.9 | 82.2 ± 15.6 | 0.21 |
| DLCOadj | ||||
| % reference | 58.6 ± 9.3 | 66.4 ± 11.0 | 72.6 ± 14.3 | 0.16 |
| KCOadj | ||||
| % reference | 80.9 ± 17.8 | 87.6 ± 17.5 | 90.3 ± 21.6 | 0.01* |
| DLNO/DLCO | ||||
| 5.28 ± 0.33 | 5.44 ± 0.64 | 5.32 ± 0.64 | 0.81 | |
| DLNO | ||||
| % reference | 50.9 ± 9.0 | 60.1 ± 9.5 | 65.0 ± 10.3 | 0.06 |
| DmCO | ||||
| % reference | 49.0 ± 14.9 | 69.4 ± 16.9 | 76.4 ± 18.1 | 0.01* |
| VC | ||||
| % reference | 53.3 ± 11.3 | 52.0 ± 11.5 | 58.5 ± 19.1 | 0.29 |
Abbreviations: DLCOadj, carbon monoxide diffusing capacity adjusted for hemoglobin; DLNO, nitric oxide diffusion capacity; DmCO, CO alveolar membrane conductance; FEV1, forced expiratory volume in 1 s; FRC, function residual capacity; FVC, forced vital capacity; KCOadj, DLCOadj adjusted for alveolar volume; RV, residual volume; TLC, total lung capacity; VC, capillary blood volume.
n = 5.
Met significance.
4. DISCUSSION
In this study of patients previously hospitalized for severe COVID‐19 pneumonitis, gas diffusion was reduced. In the earlier recovery phase at 2 months post discharge, there were similar reductions in both alveolar–capillary membrane conductance DmCO and VC. In those with more severe diffusion impairment, membrane conductance significantly improved to the normal range at subsequent follow‐up near 4 months post discharge. Reduced VC however persisted in this group, contributing to the ongoing impairment in gas diffusion.
These novel findings in recovery suggest vascular injury and/or persistent impairment of the pulmonary microcirculation plays an important role in the commonly observed gas diffusion impairment following severe COVID‐19. This is supported by the recent positive correlations between the extent of post COVID‐19 DLCO impairment and CT markers of pulmonary perfusion (Dierckx et al., 1985; Price et al., 2022), endothelial abnormalities (Mendez et al., 2022), and reduced VC (Noel‐Savina et al., 2021).
The DLNO/DLCO ratio in our cohort was within normal limits and did not change between visits. Membrane conductance and capillary volume were similarly reduced at 2 months post infection, with an identified improvement in the former only in a more severe subgroup at 4 months. This is in contrast to two previous studies that reported greater abnormality with membrane conductance and less vascular involvement (Barisione & Brusasco, 2021; Nunez‐Fernandez et al., 2021). The differences in our findings to these previous studies may be attributed to our more severe cohort, and staged testing periods following discharge. Our initial measurements identified a similarly reduced membrane conductance and VC; however, we tracked a significant improvement in membrane conductance only.
There were limitations to our study. Conducting complex physiological research during the Delta and Omicron phases of the COVID‐19 epidemic was challenging and constrained by community and institutional restrictions at times. We could not test patients during the acute phase of illness, leaving us to gather insights from those who had survived, recovered sufficiently to be discharged home, and able to attend for testing at a later date. Some patients remained too unwell to attend the clinic or were unable to meet the minimum lung volume requirements for testing criteria. In contrast, because attendance at follow‐up was voluntary, we have limited insight into changes seen in those who had an excellent improvement in respiratory symptoms and did not attend. It is evident from the data (Figure 1) that there is less follow‐up information on those with more favorable lung function at the initial visit. Nevertheless, the serial measurement in the subgroup of patients with more severe disease provides a unique insight into a condition that remains poorly understood and is increasingly recognized as a significant morbidity in previously well individuals.
The derivation of DmCO and VC is made on the assumptions of a finite θNO as considered appropriate and recommended by ERS standards (Zavorsky et al., 2017). Similar outcomes have been demonstrated in both normal and restrictive cohorts when utilizing finite versus infinite specific θNO, with linear relationships between DmCO and VC observed in both scenarios (Barisione et al., 1985). It is recognized that technical factors relating to manufacturer variations and algorithm assumptions create large changes in calculated DmCO and VC (Radtke et al., 2021). This was also observed in our laboratory, and as such we manually calculated the components, and compared to reference equations as per ERS recommendations (Zavorsky et al., 2017). Utilizing a similar method to our study, Barisione et al. (1985) found good agreement with DmCO and fibrotic changes in patients with idiopathic interstitial pneumonias. DmCO was reduced to a greater extent than VC in their cohort reflecting known parenchymal disease. Further investigation with larger and diverse cohorts are required to confirm the clinical utility of this method in clinical management.
5. CONCLUSION
DmCO is abnormal in the earlier recovery phase of severe COVID‐19 pneumonitis but improves to a significant extent in subsequent months. In contrast, reduced VC persists. Repeat testing at even longer intervals after recovery from acute illness is still required but these data raise the possibility that persisting features of acute vascular injury will contribute to physiological impairment long after severe COVID‐19 pneumonitis.
AUTHOR CONTRIBUTIONS
Concept and design: Leigh M. Seccombe and Claude S. Farah. Data collection: Leigh M. Seccombe, James R. Di Michiel, and David Heath. Data analysis: Leigh M. Seccombe and David Heath. Manuscript preparation: Leigh M. Seccombe. Manuscript edit and review: All authors.
FUNDING INFORMATION
This study was supported in part by The Jeffrey J. Pretto Memorial Research Grant.
CONFLICT OF INTEREST STATEMENT
There are no conflicts of interest to declare.
ETHICS STATEMENT
The study was approved with waiver of consent by the Sydney Local Health District Human Ethics Review Board (LNR/14/CRGH/206, NSW, Australia).
ACKNOWLEDGMENTS
We thank Mr. Brendan Kennedy and Dr. David Chapman for their assistance with DLNO/DLCO methodology.
Seccombe, L. M. , Heath, D. , Farah, C. S. , Di Michiel, J. R. , Veitch, E. M. , & Peters, M. J. (2023). Mechanisms of gas transfer impairment utilizing nitric oxide following severe COVID‐19 pneumonitis. Physiological Reports, 11, e15660. 10.14814/phy2.15660
REFERENCES
- Barisione, G. , Brusasco, C. , Garlaschi, A. , Baroffio, M. , & Brusasco, V. (1985). Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. Journal of Applied Physiology, 120, 1029–1038. [DOI] [PubMed] [Google Scholar]
- Barisione, G. , & Brusasco, V. (2021). Lung diffusing capacity for nitric oxide and carbon monoxide following mild‐to‐severe COVID‐19. Physiological Reports, 9, e14748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dierckx, W. , De Backer, W. , Lins, M. , De Meyer, Y. , Ides, K. , Vandevenne, J. , De Backer, J. , Franck, E. , Lavon, B. R. , Lanclus, M. , & Thillai, M. (1985). CT‐derived measurements of pulmonary blood volume in small vessels and the need for supplemental oxygen in COVID‐19 patients. Journal of Applied Physiology, 133, 1295–1299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Graham, B. L. , Brusasco, V. , Burgos, F. , Cooper, B. G. , Jensen, R. , Kendrick, A. , MacIntyre, N. R. , Thompson, B. R. , & Wanger, J. (2017). 2017 ERS/ATS standards for single‐breath carbon monoxide uptake in the lung. The European Respiratory Journal, 49, e70–e88. [DOI] [PubMed] [Google Scholar]
- Graham, B. L. , Steenbruggen, I. , Miller, M. R. , Barjaktarevic, I. Z. , Cooper, B. G. , Hall, G. L. , Hallstrand, T. S. , Kaminsky, D. A. , McCarthy, K. , McCormack, M. C. , Oropez, C. E. , Rosenfeld, M. , Stanojevic, S. , Swanney, M. P. , & Thompson, B. R. (2019). Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical Statement. American Journal of Respiratory and Critical Care Medicine, 200, e70–e88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Guenard, H. , Varene, N. , & Vaida, P. (1987). Determination of lung capillary blood volume and membrane diffusing capacity in man by the measurements of NO and CO transfer. Respiration Physiology, 70, 113–120. [DOI] [PubMed] [Google Scholar]
- Guenard, H. J. , Martinot, J. B. , Martin, S. , Maury, B. , Lalande, S. , & Kays, C. (2016). In vivo estimates of NO and CO conductance for haemoglobin and for lung transfer in humans. Respiratory Physiology & Neurobiology, 228, 1–8. [DOI] [PubMed] [Google Scholar]
- Hall, G. L. , Filipow, N. , Ruppel, G. , Okitika, T. , Thompson, B. , Kirkby, J. , Steenbruggen, I. , Cooper, B. G. , Stanojevic, S. , & Contributing GLI Network Members . (2021). Official ERS technical standard: Global lung function initiative reference values for static lung volumes in individuals of European ancestry. European Respiratory Journal, 57, 2000289. [DOI] [PubMed] [Google Scholar]
- Mendez, R. , Gonzalez‐Jimenez, P. , Latorre, A. , Piqueras, M. , Bouzas, L. , Yepez, K. , Ferrando, A. , Zaldivar‐Olmeda, E. , Moscardo, A. , Alonso, R. , Reyes, S. , & Menendez, R. (2022). Acute and sustained increase in endothelial biomarkers in COVID‐19. Thorax, 77, 400–403. [DOI] [PubMed] [Google Scholar]
- Noel‐Savina, E. , Viatge, T. , Faviez, G. , Lepage, B. , Mhanna, L. T. , Pontier, S. , Dupuis, M. , Collot, S. , Thomas, P. , Idoate Lacasia, J. , Crognier, L. , Bouharaoua, S. , Silva Sifontes, S. , Mazieres, J. , Prevot, G. , & Didier, A. (2021). Severe SARS‐CoV‐2 pneumonia: Clinical, functional and imaging outcomes at 4 months. Respiratory Medicine and Research, 80, 100822. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nunez‐Fernandez, M. , Ramos‐Hernandez, C. , Garcia‐Rio, F. , Torres‐Duran, M. , Nodar‐Germinas, A. , Tilve‐Gomez, A. , Rodriguez‐Fernandez, P. , Valverde‐Perez, D. , Ruano‐Ravina, A. , & Fernandez‐Villar, A. (2021). Alterations in respiratory function test three months after hospitalisation for COVID‐19 pneumonia: Value of determining nitric oxide diffusion. Journal of Clinical Medicine, 10, 2119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Price, L. C. , Garfield, B. , Bloom, C. , Jeyin, N. , Nissan, D. , Hull, J. H. , Patel, B. , Jenkins, G. , Padley, S. , Man, W. , Singh, S. , & Ridge, C. A. (2022). Persistent isolated impairment of gas transfer following COVID‐19 pneumonitis relates to perfusion defects on dual energy computed tomography. ERJ Open Research, 8, 00224‐2022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Quanjer, P. H. , Stanojevic, S. , Cole, T. J. , Baur, X. , Hall, G. L. , Culver, B. H. , Enright, P. L. , Hankinson, J. L. , Ip, M. S. , Zheng, J. , Stocks, J. , & ERS Global Lung Function Initiative . (2012). Multi‐ethnic reference values for spirometry for the 3–95‐yr age range: The global lung function 2012 equations. The European Respiratory Journal, 40, 1324–1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Radtke, T. , de Groot, Q. , Haile, S. R. , Maggi, M. , Hsia, C. C. W. , & Dressel, H. (2021). Lung diffusing capacity for nitric oxide measured by two commercial devices: A randomised crossover comparison in healthy adults. ERJ Open Research, 7, 00193–2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rubio‐Rivas, M. , Mora‐Lujan, J. M. , Formiga, F. , Arevalo‐Canas, C. , Lebron Ramos, J. M. , Villalba Garcia, M. V. , Fonseca Aizpuru, E. M. , Diez‐Manglano, J. , Arnalich Fernandez, F. , Romero Cabrera, J. L. , Garcia, G. M. , Pesqueira Fontan, P. M. , Vargas Nunez, J. A. , Freire Castro, S. J. , Loureiro Amigo, J. , Pascual Perez, M. L. R. , Alcala Pedrajas, J. N. , Encinas‐Sanchez, D. , Mella Perez, C. , … SEMI‐COVID‐19 Network . (2022). WHO ordinal scale and inflammation risk categories in COVID‐19. Comparative study of the severity scales. Journal of General Internal Medicine, 37, 1980–1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stanojevic, S. , Graham, B. L. , Cooper, B. G. , Thompson, B. R. , Carter, K. W. , Francis, R. W. , Hall, G. L. , & Global Lung Function Initiative TLCO Working Group; Global Lung Function Initiative (GLI) TLCO . (2017). Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. The European Respiratory Journal, 50, 1700010. [DOI] [PubMed] [Google Scholar]
- Thomas, M. , Price, O. J. , & Hull, J. H. (2021). Pulmonary function and COVID‐19. Current Opinion in Physiology, 21, 29–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Torres‐Castro, R. , Vasconcello‐Castillo, L. , Alsina‐Restoy, X. , Solis‐Navarro, L. , Burgos, F. , Puppo, H. , & Vilaro, J. (2021). Respiratory function in patients post‐infection by COVID‐19: A systematic review and meta‐analysis. Pulmonology, 27, 328–337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wanger, J. , Clausen, J. L. , Coates, A. , Pedersen, O. F. , Brusasco, V. , Burgos, F. , Casaburi, R. , Crapo, R. , Enright, P. , van der Grinten, C. P. , Gustafsson, P. , Hankinson, J. , Jensen, R. , Johnson, D. , Macintyre, N. , McKay, R. , Miller, M. R. , Navajas, D. , Pellegrino, R. , & Viegi, G. (2005). Standardisation of the measurement of lung volumes. The European Respiratory Journal, 26, 511–522. [DOI] [PubMed] [Google Scholar]
- Zavorsky, G. S. , Hsia, C. C. , Hughes, J. M. , Borland, C. D. , Guenard, H. , van der Lee, I. , Steenbruggen, I. , Naeije, R. , Cao, J. , & Dinh‐Xuan, A. T. (2017). Standardisation and application of the single‐breath determination of nitric oxide uptake in the lung. The European Respiratory Journal, 49, 1600962. [DOI] [PubMed] [Google Scholar]